Non-resectable hepatocellular carcinoma (HCC)
Conditions
Brief summary
The proportion of patients with TACE failure and treated with lenvatinib who have a LT
Detailed description
Time to progression under lenvatinib before LT by imaging. Progression will be based on RECIST and mRECIST., Progression under lenvatinib before LT by imaging. Progression will be based on RECIST and mRECIST., Response rate before LT by imaging, Response rate by liver specimen pathology after the LT, Recurrence rate after LT by imaging, Evaluate Safety by AE and SAE (using current CTCAE), The endpoints associated to the immunophenotyping of peripheral blood immune cell population will be on the ancillary analyses.
Interventions
Sponsors
Assistance Publique Hopitaux De Paris
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients with TACE failure and treated with lenvatinib who have a LT | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to progression under lenvatinib before LT by imaging. Progression will be based on RECIST and mRECIST., Progression under lenvatinib before LT by imaging. Progression will be based on RECIST and mRECIST., Response rate before LT by imaging, Response rate by liver specimen pathology after the LT, Recurrence rate after LT by imaging, Evaluate Safety by AE and SAE (using current CTCAE), The endpoints associated to the immunophenotyping of peripheral blood immune cell population will be on the ancillary analyses. | — |
Countries
France
Outcome results
None listed